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ABSTRACT
Objective: This study aimed to compare the effectiveness and safety of fixed dose combination (FDC) versus separate (separate formulation [SF]) 
antituberculosis (TB) formulations in patients with bacteriologically confirmed pulmonary TB.
Methods: Data were collected retrospectively from patient records, which included all newly diagnosed bacteriologically confirmed pulmonary 
TB patients treated with first category FDC or SF between January 2014 and January 2017 at the Dr. Esnawan Antariksa Hospital. The efficacy of 
the formulations was determined according to acid-fast bacilli (AFB) sputum smear conversion at the end of the intensive phase (month 2), after 
6 months of therapy, and after the extended treatment phase (month 3). Adverse drug reactions (ADRs) during treatments were recorded as safety 
outcomes. Chi-square tests were used to analyze the differences between the groups.
Results: On comparing patients treated with FDC (n=33) and SF (n=30), rates of sputum conversions did not differ significantly after 2 months 
(83.3% vs. 78.7%, p=0.693) and the intensive phase was extended by 1 month for patients with conversion failures at this time point. One of seven 
patients in the FDC group did not achieve sputum conversion during the extended phase and was recorded as a medication failure. At the end of 
continuation phase, all other subjects achieved sputum conversion. The overall frequencies of ADRs were not significantly higher in the FDC group 
than that in the SF group (36.4% vs. 23.3%, p=0.260).
Conclusion: No differences in effectiveness and safety profiles were identified between first category FDC and separate anti TB formulations.
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INTRODUCTION
According to the global tuberculosis (TB) Report, 2014, from the World 
Health Organization, TB affected 9.6 million patients globally and caused 
mortality in 1.2 million patients. India, Indonesia, and China had the 
highest numbers of TB patients, representing 23%, 10%, and 10% of 
all patients, respectively [1]. The Global TB Report 2014 also states 
that 5.4 million new cases of TB were confirmed in bacteriological studies, 
and 0.3 million of these were relapse cases that had previously been cured. 
The percentage relapse rates among TB patients were 33% in India, 9% 
in China, 5.3% in South Africa, 5% in Russia, and 2.6% in Indonesia [1,2].
Pulmonary TB was confirmed in 330,910 cases in Indonesia during 
2015 and was higher than in the previous year (324,538 cases) [3]. In 
Jakarta, 24,500 cases were identified during 2012, corresponding with 
a prevalence rate of 256 per 100,000 people, and the Case Fatality Rate 
was 2 per 100,000 people living in Jakarta [3].
The relative efficacies of fixed-dose combination (FDC) and separate 
formulation (SF) anti TB therapies remain questionable. In a study 
during 2011, Lienhardt et al. showed that FDC and FC had similar 
effectiveness, but patient compliance was better in the FDC group [4]. 
Aseffa et al. 2016 also confirmed that FDC and SF were equally effective 
as cures for pulmonary TB [5], and in an Indonesian study by Tabrani 
and Sputum 2007, no differences in AFB sputum conversion were 
found between FDC and SF groups at the end of the intensive phase. 
However, no published trials compare AFB sputum conversion during 
the continuation phase [6].
In 2003, Immanuel et al. stated that the bioavailability of rifampicin 
was decreased when administered concomitantly with other anti-
TB agents [7]. Singh et al. also showed decreases in rifampicin 
bioavailability following formulation into tablets with isoniazid [8].
In an Indonesian study conducted by van Crevel et al. during 2002, 62 
TB patients were prescribed with the anti-TB agent 2RHZE at doses of 
450, 300, 1500, and 750 mg during the intensive phase and continued 
with 4R3H3 at 450- and 600-mg doses during the continuation 
phase. These investigators reported a 70% decrease in the rifampicin 
plasma concentrations, resulting in subtherapeutic plasma levels of 
<4 mg/L [9]. In a study conducted in South Sulawesi by Suryanto et al. 
during 2008, the incidence of pulmonary TB relapse after successful 
FDC treatments remained higher (10.1%) than that after successful SF 
treatments (2.7%) [10].
There remains a lack of information about differences in effectiveness 
and safety of FDC and SF during intensive and continuation phases 
in Indonesia. Thus, we evaluated effectiveness and safety in FDC SF 
treatment groups of patients with bacteriological confirmed pulmonary 
TB during January 2014–January 2017 at the Dr. Esnawan Antariksa 
hospital in Halim Perdana Kusuma.
METHODS
Study design
This retrospective study was conducted using secondary data from the 
medical records of patients. Bacteriologically confirmed TB patients 
who were prescribed anti-TB first category FDC or SF between January 
2014 and January 2017 were recruited from the Dr. Esnawan Antariksa 
Hospital at Jakarta. The Ethics Committee of the Faculty of Medicine 
at Universitas Indonesia approved the study (No: 811/UN2.F1/
ETIK/2017).
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Population and study samples
The data were collected from all the clinical records of new-onset 
bacteriologically confirmed TB patients who were prescribed first 
category anti-TB FDC or SF treatments. The included patients were 
male or female and were 15–75 years old. Excluded from the analyzes 
were patients with HIV infections, incomplete medical records, 
extra-pulmonary TB, or multiple TB infections (pulmonary TB and 
extrapulmonary TB) were excluded from analyses.
Outcomes
Effectiveness was evaluated according to sputum conversion at the 
end of the intensive (month 2) and continuation phases (month 6) of 
therapy. Safety outcomes were the adverse drug reactions (ADRs) that 
occurred during treatment.
RESULTS AND DISCUSSION
A total of 125 patients with new-onset pulmonary TB were prescribed 
first category anti-TB agents, and 75 of these were bacteriologically 
confirmed. One patient was excluded due to incomplete data, and 
11 were excluded because they did not continue treatments at the 
Dr. Esnawan Antariksa Hospital. The final cohort included 33 patients 
in the FDC group and 30 patients in the SF group, and treatment groups 
had similar mean baseline characteristics (Table 1).
Frequencies of sputum conversions at the end of the intensive phase, the 
extended phase, and the continuation phase are presented in Table 2. 
Sputum conversion rates at the end of the intensive phase were higher in 
the SF group (83.3%) than in the FDC group (78.8%), but this difference 
was not significant (p=0.693). According to the, 2014, Indonesia National 
guidelines for TB treatment, the intensive phase was extended for one 
more month (extended phase) in patients with conversion failure at 
2 months. At the end of the extended phase, sputum conversion in the FDC 
group was 85.7% and that in the SF group was 100%. One patient in the 
FDC group did not achieve sputum conversion during the extended phase, 
and the patient was considered a medication failure, was excluded from 
the study, and received second category anti-TB treatment. At the end of 
the continuation phase, all the subjects achieved sputum conversion.
The safety outcomes were evaluated by comparing the incidence of 
ADRs in the treatment groups (Table 3). Two major ADRs occurred in 
the FDC group, and these were a hyper-reactivity reaction and hepatitis. 
Minor ADRs were abdominal discomfort and nausea (19.4%), flu-like 
syndrome (4.8%), pruritus (1.6%), and paresthesia (1.6%). The total 
frequencies of ADRs did not differ significantly between FDC and SF 
groups (36.4% vs. 23.3%, respectively, p=0.260).
DISCUSSION
In this study, 7 patients (21.2%) in the FDC group and 5 patients 
(16.7%) in the SF group failed to achieve sputum conversion at the 
end of the intensive phase. After 1-month extensions of the intensive 
phase (extended phase), all the 5 patients in the SF group achieved 
conversion, whereas one patient in the FDC group failed. Since there 
was no data of anti-TB resistance in this patient, we were unable to 
determine whether the effectiveness of FDC was inferior to that of SF. 
Similarly, in a 2008 study, Tabrani showed no differences in sputum 
conversion between FDC and SF groups at the 4th and 8th weeks of 
treatment [6]. In 2014, Caesar showed higher sputum conversion 
rates at the end of an intensive phase in the FDC group (72.72%) than 
in the SF group (65.90%) but failed to show statistical significance 
(p=0.644) [11]. Similarly, Lienhardt et al. showed no significant 
differences in effectiveness and safety between FDC and SF treatment 
groups in 2011 [12].
Most of the previous studies of TB treatments only report sputum 
conversion at the end of the intensive phase [6,11,12]. In this study, we 
additionally evaluated sputum conversions at the continuation phase 
with the intention of resolving questions regarding the effectiveness of 
intermittent anti-TB regimens during the continuation phase. One of 
our patients failed to achieve conversion by the end of the extended 
phase, indicating medication failure, and subsequently received second 
category anti-TB treatment. In the remaining patients that received 
treatment during the continuation phase, sputum conversion was 
maintained to the end of month 6 in both the FDC and the SF groups.
Finally, whereas major ADRs only occurred in the FDC group, the overall 
frequency of ADRs did not differ significantly between the FDC and SF 
groups.
Table 1: Baseline characteristics
Characteristic FDC SF p
Total patients - n (%) 33 (52.4) 30 (47.6)
Age - n (%)
15–54 years 28 (84.8) 21 (70) 0.157
55–74 years 5 (15.2) 9 (30)
Sex - n (%)
Men 16 (48.5) 18 (58.6) 0.360
Women 17 (51.5) 12 (41.4)
BMI (kg/m2) - n (%)
Underweight (<18.5) 2 (6.1) 11 (37.9) 0.105
Healthy (18.5–24.9) 24 (72.7) 18 (58.6)
Overweight (25–26.9) 3 (9.1) 0 (0)
Obese (≥27) 4 (12.1) 1 (3.4)
Smoking - n (%)
Smoker 33 (100) 29 (97.0)
Non smoker 0 (0) 1 (3.0)
AFB initial - n (%)
+1 33 (100) 28 (93.1)
+2 0 (0) 1 (3.4)
+3 0 (0) 1 (3.4)
Comorbid - n (%)
Diabetes mellitus 6 (18.2) 6 (20.7) 0.854
Hepatitis 0 (0) 1 (3.4) -
GI tract disorder 2 (6.1) 3 (10.3) 0.662
Allergic reactions 1 (3.0) 0 (0) -
Adherence–n (%)
Adhere 24 (72.7) 20 (65.5) 0.601
Non-adhere 9 (27.3) 10 (34.5)
AFB: Acid-fast bacilli, BMI: Body mass index, FDC: Fixed-dose combination, 
SF: Separate formulation, GI: Gastrointestinal 
Table 2: Sputum conversion rates at the ends of intensive, 
extended, and continuation phases



















FDC: Fixed-dose combination, SF: Separate formulation, n: Numbers of patients 
with or without sputum conversion, N: total numbers of patients in treatment 
groups. *One patient was excluded due to conversion failure
Table 3: Frequencies of ADRs in FDC and SF groups
ADRs FDC n=33 SF n=30
Major - n (%) 2 (6.1) 0 (0)
Hypereactivity reactions 1 (3.0) 0 (0)
Hepatitis 1 (3.0) 0 (0)
Minor - n (%) 10 (30.3) 0 (0)
Abdominal discomfort 8 (24.2) 7 (23.3)
Pruritus 0 (0) 4 (13.3)
Flu-like syndrome 2 (6.1) 1 (3.3)
Paresthesia 0 (0) 1 (3.3)
Major+minor 12 (36.4) 7 (23.3)
ADRs: Adverse drug reactions, FDC: Fixed-dose combination, SF: Separate 
formulation, n: Frequencies of ADRs, N: Total numbers of patients
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The small sample size limited the significance of the differences 
between treatment groups.
CONCLUSION
Sputum conversion rates at the end of the intensive phase were 
higher in the SF group (83.3%) than in the FDC group (78.8%), but 
this difference was not significant (p=0.693). The total frequencies of 
ADRs did not differ significantly between FDC and SF groups (36.4% 
vs. 23.3%, respectively, p=0.260). Thus, no significant differences in 
effectiveness and safety profiles of the first category FDC and SF anti-TB 
formulations were found in this study, warranting further studies with 
larger sample sizes.
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